Previous studies in animals have found that high doses of CPF, which inhibits plasma butyryl cholinesterase and brain acetylcholinesterase activity, can promote obesity and glucose dysregulation through mechanisms that are poorly defined but may involve increases in energy intake and/or alterations in the gut microbiome34–39. The gene discussed is ACHE; the disease is obesity due to melanocortin 4 receptor deficiency.